Drug Profile
Research programme: tau targeting therapeutics and diagnostics - TauRx Pharmaceuticals
Alternative Names: G3Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator TauRx Pharmaceuticals
- Class Antidementias; Diagnostic agents
- Mechanism of Action Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 28 Dec 2022 Research programme: tau targeting therapeutics and diagnostics - TauRx Pharmaceuticals is still in preclinical development for Alzheimer's-disease (Diagnosis) in Singapore (PO) (TauRx Pharmaceuticals website, December 2022)
- 28 Dec 2022 Research programme: tau targeting therapeutics and diagnostics - TauRx Pharmaceuticals is still in preclinical development for Alzheimer's-disease in Singapore (PO) (TauRx Pharmaceuticals website, December 2022)
- 28 Mar 2020 No recent reports of development identified for research development in Alzheimer's-disease(Diagnosis) in Singapore (PO)